[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multiple-myeloma-and-plasma-cell-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multiple-myeloma-and-plasma-cell-neoplasm":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,201,237,261],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":33,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":200},"100143410","registry-of-older-patients-with-cancer-100143410",false,"NCT01137825","Registry of Older Patients With Cancer","Carolina Senior: UNC Registry for Older Cancer Patients","DISEASE CHARACTERISTICS:\n\n* Patients must have an appointment at the North Carolina Cancer Hospital and agree to complete the Geriatric Assessment NOTE: Not all patients included in the registry will ultimately be diagnosed with cancer. Patients who complete a GA and are not diagnosed with cancer will remain in the database, but will be categorized into a separate group and will not have their medical records accessed.\n\nPATIENT CHARACTERISTICS:\n\n* Able to read and speak English\n\nPRIOR CONCURRENT THERAPY:\n\n* Not specified","ALL","65 Years",{"count":19,"type":20},3000,"ESTIMATED","OBSERVATIONAL","RATIONALE: Gathering information about older patients with cancer may help the study of cancer in the future.\n\nPURPOSE: This research study is gathering information from older patients with cancer into a registry.",[24,25,26,27,28,29,30,31,32],"Chronic Myeloproliferative Disorders","Cognitive\u002FFunctional Effects","Leukemia","Lymphoma","Lymphoproliferative Disorder","Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic Syndromes","Myelodysplastic\u002FMyeloproliferative Neoplasms","Unspecified Adult Solid Tumor, Protocol Specific",[34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187],"cognitive\u002Ffunctional effects","unspecified adult solid tumor, protocol specific","accelerated phase chronic myelogenous leukemia","acute undifferentiated leukemia","adult acute lymphoblastic leukemia in remission","adult acute myeloid leukemia in remission","adult acute myeloid leukemia with 11q23 (MLL) abnormalities","adult acute myeloid leukemia with inv(16)(p13;q22)","adult acute myeloid leukemia with t(15;17)(q22;q12)","adult acute myeloid leukemia with t(16;16)(p13;q22)","adult acute myeloid leukemia with t(8;21)(q22;q22)","atypical chronic myeloid leukemia, BCR-ABL negative","blastic phase chronic myelogenous leukemia","chronic myelomonocytic leukemia","chronic phase chronic myelogenous leukemia","mast cell leukemia","meningeal chronic myelogenous leukemia","progressive hairy cell leukemia, initial treatment","prolymphocytic leukemia","recurrent adult acute lymphoblastic leukemia","recurrent adult acute myeloid leukemia","recurrent adult T-cell leukemia\u002Flymphoma","refractory chronic lymphocytic leukemia","refractory hairy cell leukemia","relapsing chronic myelogenous leukemia","secondary acute myeloid leukemia","stage 0 chronic lymphocytic leukemia","stage I adult T-cell leukemia\u002Flymphoma","stage I chronic lymphocytic leukemia","stage II adult T-cell leukemia\u002Flymphoma","stage II chronic lymphocytic leukemia","stage III adult T-cell leukemia\u002Flymphoma","stage III chronic lymphocytic leukemia","stage IV adult T-cell leukemia\u002Flymphoma","stage IV chronic lymphocytic leukemia","T-cell large granular lymphocyte leukemia","untreated adult acute lymphoblastic leukemia","untreated adult acute myeloid leukemia","untreated hairy cell leukemia","recurrent adult Hodgkin lymphoma","stage I adult Hodgkin lymphoma","stage II adult Hodgkin lymphoma","stage III adult Hodgkin lymphoma","stage IV adult Hodgkin lymphoma","anaplastic large cell lymphoma","angioimmunoblastic T-cell lymphoma","cutaneous B-cell non-Hodgkin lymphoma","recurrent cutaneous T-cell non-Hodgkin lymphoma","stage I cutaneous T-cell non-Hodgkin lymphoma","stage II cutaneous T-cell non-Hodgkin lymphoma","stage III cutaneous T-cell non-Hodgkin lymphoma","stage IV cutaneous T-cell non-Hodgkin lymphoma","recurrent mycosis fungoides\u002FSezary syndrome","stage I mycosis fungoides\u002FSezary syndrome","stage II mycosis fungoides\u002FSezary syndrome","stage III mycosis fungoides\u002FSezary syndrome","stage IV mycosis fungoides\u002FSezary syndrome","adult grade III lymphomatoid granulomatosis","adult nasal type extranodal NK\u002FT-cell lymphoma","Waldenstrom macroglobulinemia","extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue","nodal marginal zone B-cell lymphoma","splenic marginal zone lymphoma","contiguous stage II adult Burkitt lymphoma","contiguous stage II adult diffuse large cell lymphoma","contiguous stage II adult diffuse mixed cell lymphoma","contiguous stage II adult diffuse small cleaved cell lymphoma","contiguous stage II adult immunoblastic large cell lymphoma","contiguous stage II adult lymphoblastic lymphoma","contiguous stage II grade 1 follicular lymphoma","contiguous stage II grade 2 follicular lymphoma","contiguous stage II grade 3 follicular lymphoma","contiguous stage II mantle cell lymphoma","contiguous stage II marginal zone lymphoma","contiguous stage II small lymphocytic lymphoma","stage I adult Burkitt lymphoma","stage I adult diffuse large cell lymphoma","stage I adult diffuse mixed cell lymphoma","stage I adult diffuse small cleaved cell lymphoma","stage I adult immunoblastic large cell lymphoma","stage I adult lymphoblastic lymphoma","stage I grade 1 follicular lymphoma","stage I grade 2 follicular lymphoma","stage I grade 3 follicular lymphoma","stage I mantle cell lymphoma","stage I marginal zone lymphoma","stage I small lymphocytic lymphoma","noncontiguous stage II adult Burkitt lymphoma","noncontiguous stage II adult diffuse large cell lymphoma","noncontiguous stage II adult diffuse mixed cell lymphoma","noncontiguous stage II adult diffuse small cleaved cell lymphoma","noncontiguous stage II adult immunoblastic large cell lymphoma","noncontiguous stage II adult lymphoblastic lymphoma","noncontiguous stage II grade 1 follicular lymphoma","noncontiguous stage II grade 2 follicular lymphoma","noncontiguous stage II grade 3 follicular lymphoma","noncontiguous stage II mantle cell lymphoma","noncontiguous stage II marginal zone lymphoma","noncontiguous stage II small lymphocytic lymphoma","stage III adult Burkitt lymphoma","stage III adult diffuse large cell lymphoma","stage III adult diffuse mixed cell lymphoma","stage III adult diffuse small cleaved cell lymphoma","stage III adult immunoblastic large cell lymphoma","stage III adult lymphoblastic lymphoma","stage III grade 1 follicular lymphoma","stage III grade 2 follicular lymphoma","stage III grade 3 follicular lymphoma","stage III mantle cell lymphoma","stage III marginal zone lymphoma","stage III small lymphocytic lymphoma","stage IV adult Burkitt lymphoma","stage IV adult diffuse large cell lymphoma","stage IV adult diffuse mixed cell lymphoma","stage IV adult diffuse small cleaved cell lymphoma","stage IV adult immunoblastic large cell lymphoma","stage IV adult lymphoblastic lymphoma","stage IV grade 1 follicular lymphoma","stage IV grade 2 follicular lymphoma","stage IV grade 3 follicular lymphoma","stage IV mantle cell lymphoma","stage IV marginal zone lymphoma","stage IV small lymphocytic lymphoma","recurrent adult Burkitt lymphoma","recurrent adult diffuse large cell lymphoma","recurrent adult diffuse mixed cell lymphoma","recurrent adult diffuse small cleaved cell lymphoma","recurrent adult grade III lymphomatoid granulomatosis","recurrent adult immunoblastic large cell lymphoma","recurrent adult lymphoblastic lymphoma","recurrent grade 1 follicular lymphoma","recurrent grade 2 follicular lymphoma","recurrent grade 3 follicular lymphoma","recurrent mantle cell lymphoma","recurrent marginal zone lymphoma","recurrent small lymphocytic lymphoma","intraocular lymphoma","post-transplant lymphoproliferative disorder","chronic eosinophilic leukemia","chronic neutrophilic leukemia","primary myelofibrosis","essential thrombocythemia","polycythemia vera","extramedullary plasmacytoma","isolated plasmacytoma of bone","stage I multiple myeloma","stage II multiple myeloma","stage III multiple myeloma","primary systemic amyloidosis","refractory multiple myeloma","de novo myelodysplastic syndromes","previously treated myelodysplastic syndromes","secondary myelodysplastic syndromes","myelodysplastic\u002Fmyeloproliferative neoplasm, unclassifiable","RECRUITING","2026-06-24",{"date":191,"type":192},"2026-06-29","ACTUAL",{"date":194,"type":4},"2009-09",{"date":196,"type":20},"2030-12",{"name":198,"class":199},"UNC Lineberger Comprehensive Cancer Center","OTHER",7,{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":208,"sex":16,"minAge":209,"maxAge":210,"enrollmentInfo":211,"targetDuration":4,"studyType":213,"phases":214,"briefSummary":217,"conditions":218,"keywords":221,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":236},"100617536","phase-2-68ga-bcma-petct-in-multiple-myeloma-100617536","NCT07319897","68Ga-BCMA PET\u002FCT in Multiple Myeloma","A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET\u002FCT for Targeting BCMA Expression in Multiple Myeloma.","Inclusion Criteria:\n\n* patients with suspected or previously diagnosed multiple myeloma (MM) who were scheduled for bone marrow aspiration or tissue biopsy within two weeks, including those undergoing initial diagnostic evaluation or follow-up\u002Fre-evaluation for disease monitoring or relapse;\n* patients with confirmed symptomatic MM;\n* ability to understand and voluntarily sign written informed consent;\n* ability to comply with study procedures;\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤2.\n\nExclusion Criteria:\n\n* pregnancy or lactation;\n* inability to comprehend study procedures or cooperate with protocol requirements;\n* any other condition judged by the investigator to potentially interfere with study participation.",true,"18 Years","80 Years",{"count":212,"type":20},300,"INTERVENTIONAL",[215,216],"PHASE2","PHASE3","This is a prospective, multicenter diagnostic imaging study designed to evaluate the diagnostic accuracy and clinical utility of BCMA-targeted positron emission tomography\u002Fcomputed tomography (PET\u002FCT) in patients with multiple myeloma and related plasma cell disorders. The study aims to non-invasively visualize and quantify whole-body BCMA expression and to assess its role in the detection of active disease and disease heterogeneity.",[219,220,29],"Multiple Myeloma","Multiple Myeloma and Malignant Plasma Cell Neoplasms",[222,223,224,225,226],"multiple myeloma","bcma","PET\u002FCT","diagnosis","multicenter","2026-06-16",{"date":229,"type":192},"2026-06-22",{"date":231,"type":192},"2025-12-25",{"date":233,"type":20},"2027-12-30",{"name":235,"class":199},"Peking University First Hospital",5,{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":16,"minAge":209,"maxAge":244,"enrollmentInfo":245,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":247,"conditions":248,"keywords":250,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":260},"100143396","tissue-blood-and-body-fluid-sample-collection-from-patients-with-hematologic-cancer-100143396","NCT01137643","Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer","Tissue Procurement For Hematolymphoid Conditions","DISEASE CHARACTERISTICS:\n\n* Diagnosis of abnormal hematopoietic\u002Flymphoid cancer, including any of the following:\n\n  * Acute myeloid leukemia\n  * Acute lymphoblastic leukemia\n  * Chronic myelogenous leukemia\n  * Chronic lymphoid leukemia\n  * Non-Hodgkin lymphoma\n  * Hodgkin lymphoma\n  * Myelodysplastic syndromes\n  * Myeloproliferative disorders\n  * Multiple myeloma\n  * Waldenstrom macroglobulinemia\n  * Aplastic anemia\n  * Any other diseases that generate abnormalities in either number, function, or both of any cell type of hematolymphoid lineage\n* Patients who are being evaluated at the hematology\u002Foncology clinics of the University of North Carolina Hospitals, at the stem cell transplant clinic, or in the hospital\n\nPATIENT CHARACTERISTICS:\n\n* Not specified\n\nPRIOR CONCURRENT THERAPY:\n\n* Not specified","120 Years",{"count":246,"type":20},15000,"RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future.\n\nPURPOSE: This research study is collecting and storing blood and tissue samples from patients being evaluated for hematologic cancer.",[24,26,27,28,29,30,31,249],"Nonmalignant Neoplasm",[36,37,38,39,40,41,42,43,44,45,46,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,251],"aplastic anemia","2025-10-23",{"date":254,"type":192},"2025-10-27",{"date":256,"type":4},"2009-07",{"date":258,"type":20},"2040-07",{"name":198,"class":199},1,{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":16,"minAge":209,"maxAge":244,"enrollmentInfo":4,"targetDuration":4,"studyType":213,"phases":4,"briefSummary":268,"conditions":269,"keywords":271,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":278,"leadSponsor":280,"locationsCount":260},"100128032","3-deoxy-3-18f-fluorothymidine-pet-imaging-in-patients-with-cancer-100128032","NCT00935090","3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer","Use of [F-18] FLT for Imaging With Positron Emission Tomography (PET)","DISEASE CHARACTERISTICS:\n\n* Meets one of the following criteria:\n\n  * Histologically confirmed solid tumor or hematologic malignancy\n  * Awaiting biopsy or surgery for cancer evaluation of a mass detected on exam or standard imaging\n\nPATIENT CHARACTERISTICS:\n\n* Able to lie still in the PET scanner\n* Girth and weight must be suitable to enter the gantry\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n\nPRIOR CONCURRENT THERAPY:\n\n* Not specified","RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-\\[18F\\] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment.\n\nPURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.",[270,24,26,27,28,29,30,31,32],"Brain and Central Nervous System Tumors",[35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,272,273,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187],"primary central nervous system non-Hodgkin lymphoma","primary central nervous system Hodgkin lymphoma","2025-07-02",{"date":276,"type":192},"2025-07-08",{"date":194,"type":192},{"date":279,"type":20},"2028-05",{"name":281,"class":199},"Barbara Ann Karmanos Cancer Institute"]